Monica Castro, et al. v. Abbott Laboratories, Inc.

Summary

The United States District Court for the Northern District of Illinois ruled on Abbott Laboratories, Inc.’s motion to dismiss claims concerning the labeling and advertising of Similac toddler drinks. The court allowed the state consumer-protection claims, unjust-enrichment claim, and implied-warranty claim to proceed, while dismissing the express-warranty, intentional-misrepresentation, and negligent-misrepresentation claims. The court also declined at this stage to dismiss the request for injunctive relief.

Holdings

1. The plaintiffs adequately pleaded their fraud-based claims with particularity by identifying who allegedly committed the fraud, what the alleged fraud was, when and where it occurred, and how Abbott allegedly used the labeling and packaging to mislead consumers.
2. The plaintiffs plausibly alleged that a reasonable consumer could be deceived into believing that Abbott's Stage 3 toddler formula was the nutritionally recommended next product after infant formula; dismissal was therefore unwarranted at the pleading stage.
3. The plaintiffs plausibly alleged that Abbott's front-label health representations could mislead reasonable consumers despite sugar disclosures elsewhere on the product, so the added-sugar theory survived dismissal.
4. The unjust-enrichment claim in Count XIII was adequately pleaded because the statutory consumer-protection claims on which it rested also survived dismissal.
5. Count XI failed because the plaintiffs did not allege that Abbott's affirmations or descriptions on the cans were themselves false or that the products failed to conform to them.
6. Count XII was adequately pleaded because the allegation that regular consumption of the toddler drinks was detrimental rather than beneficial to toddler health plausibly alleged that the products were not fit for their ordinary nutritional purpose.
7. Counts XIV and XV failed because the plaintiffs did not identify a false statement of material fact; allegations that otherwise nonfalse statements created an incorrect overall impression about the products' healthiness were insufficient.
8. The court declined to dismiss the request for injunctive relief at the pleading stage because a remedy is not a standalone claim and the complaint plausibly alleged claims for relief.

Questions Presented

1. Whether the plaintiffs plausibly alleged that Abbott's labeling and advertising could deceive a reasonable consumer under the consumer-protection and false-advertising laws of the nine states identified in the complaint.
2. Whether the plaintiffs pleaded the alleged labeling fraud with particularity under Federal Rule of Civil Procedure 9(b).
3. Whether the plaintiffs stated a claim for unjust enrichment.
4. Whether the plaintiffs stated a claim for breach of express warranty.
5. Whether the plaintiffs stated a claim for breach of the implied warranty of merchantability.
6. Whether the plaintiffs stated claims for intentional and negligent misrepresentation.
7. Whether the court should dismiss the request for injunctive relief for lack of standing at the motion-to-dismiss stage.

Disposition

other